Atypical hemolytic uremic syndrome in a patient with HIV treated with eculizumab: A case report
Danilo E.Trujillo González,
Dagoberto Duarte Misol,
Nicolás Ariza Ordoñez,
Fabian Andres Salgado Zamora,
Henry A. Millan Prada,
Eduardo Zuñiga R,
Alejandra Molano Triviño
Affiliations
Danilo E.Trujillo González
Nephrology Fellow, School of Medicine and Health Science - Universidad del Rosario, Internal Medicine Deparment - La Cardio, Bogotá, Colombia; Correspondence to: La Cardio – Fundación Cardioinfantil, Calle 163A # 13B-60, Bogotá, Colombia.
Dagoberto Duarte Misol
Internal Medicine Resident, School of Medicine and Health Science - Universidad del Norte, Barranquilla, Colombia
Nicolás Ariza Ordoñez
Internal Medicine Resident, School of Medicine and Health Science - Universidad del Rosario, Bogotá, Colombia
Fabian Andres Salgado Zamora
Nephrology Fellow, School of Medicine and Health Science - Universidad del Rosario, Internal Medicine Deparment - La Cardio, Bogotá, Colombia
Henry A. Millan Prada
Infectious disease specialist. La Cardio, Bogotá, Colombia
Thrombotic microangiopathy defines a group of pathologies characterized by microvascular dysfunction with the concurrence of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. It represents the most frequent microvascular manifestation of human immunodeficiency virus (HIV) infection. We report the case of a man in the seventh decade of life with a recent diagnosis of infection by HIV, who develops hemolytic uremic syndrome, requiring continuous renal replacement therapy and plasma replacement therapy, without response, ADAMTS13 with preserved activity, ruling out other etiologies (infectious, metabolic, and genetic) with successful response to eculizumab.
